# a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients

> **NCT04008888** · NA · UNKNOWN · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 50 (estimated)

## Conditions studied

- Multiple Myeloma
- Plasma Cell Leukemia
- Extramedullary Plasmacytoma
- Loss of Chromosome 17p
- t(14;16)
- t(4;14)
- T(14;20)
- 1Q21 Amplification
- Complex Karyotype

## Interventions

- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation
- **PROCEDURE:** Autologous Hematopoietic Stem Cell Transplantation x 1 or x 2
- **DRUG:** Melphalan Given IV
- **DRUG:** Fludarabine Injection
- **DRUG:** PI and dexamethasone as maintenance therapy
- **DRUG:** PI+IMids+Dexamethasone as Consolidated Chemotherapy

## Key facts

- **NCT ID:** NCT04008888
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01-05
- **Primary completion:** 2020-01-01
- **Final completion:** 2020-08-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2019-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04008888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04008888, "a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04008888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*